News
FDA approves generic versions of blood thinner Plavix
The U.S. Food and Drug Administration approved generic versions of the blood thinning drug Plavix, which helps reduce the risk of heart attack and...
News
Amgen’s BiTE® antibody blinatumomab achieved high rate of complete response
Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR)...
News
In drug-approval race, US FDA ahead of Canada, Europe
The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a...
News
Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India
The Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years...
News
Serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis
Recently announced results from two-year CATT (Comparison of Age-related macular degeneration Treatment Trials) adds to the growing body of evidence, including CATT 1-year data...
News
AstraZeneca to acquire Ardea Biosciences for $1 billion
AstraZeneca and Ardea Biosciences, Inc. have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company...
News
Key protein responsible for controlling nerve cell protection
A key protein, which may be activated to protect nerve cells from damage during heart failure or epileptic seizure, has been found to regulate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.